Panion & BF Biotech held its third-quarter earnings conference yesterday, reporting that despite competition from generic drugs, its new drug, Nephoxil, has potential opportunities. With phosphate binders set to be included in bundled payment systems, the drug may qualify for Transitional Drug Add-On Payment (TDAPA) benefits. Additionally, sales in Japan have shown steady growth, and Nephoxil has been submitted for regulatory registration in Europe this year.
For the first nine months of this year, Panion & BF Biotech recorded consolidated revenue of NT$1.5 billion, marking an 11% year-over-year increase. Gross profit reached NT$800 million, up 12%, while after-tax net income surged by 93% to NT$91.71 million. Earnings per share (EPS) were NT$1.07. The company invested NT$190 million in R&D, representing 12.5% of its revenue, a proportion that has increased annually. Panion emphasized its commitment to R&D as a long-term growth strategy to maintain its competitive edge in the market.
Regarding Nephoxil's licensing status, Panion noted that while its U.S. partner faces competition from generics, the inclusion of phosphate binders in bundled payment systems could support continued sales momentum. Japan has yet to face generic challenges, and sales there are steadily growing.
Panion highlighted that Nephoxil was submitted for regulatory registration in Europe this year. Post-launch, it is expected to generate additional licensing revenue. In South Korea, following the termination of a distribution agreement with KKKR, Panion is negotiating with a new distributor and expanding into Thailand and other Southeast Asian markets to further its global footprint.
Panion also shared updates on Nephoxil's development: a new 1,000 mg tablet formulation and additional indications are planned for regulatory submission by year-end, with concurrent health insurance review. Its active pharmaceutical ingredient, ferric citrate, has been registered in the U.S. Drug Master File (DMF) system, with an annual production capacity projected at 100 tons. This cost advantage positions Panion as a key supplier to its U.S. and Japanese licensing partners.
Leveraging Nephoxil as a stable cash flow driver, Panion will focus on new formulations and indications as its core drug development strategy. The company aims to accelerate product timelines and strengthen market competitiveness for existing offerings. In the field of innovative diagnostics, Panion is concentrating on all-in-one testing technologies and applications for home use, targeting the healthcare, long-term care, and post-aesthetic treatment markets. These initiatives will inject fresh growth momentum into operations, presenting a diversified vision for the company's future.
Resource: 寶齡富錦前三季每股賺 1.07 元！新藥拿百磷已送歐洲查驗登記
